BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 29506913)

  • 1. Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era.
    Waziry R; Gomaa A; Waked I; Dore GJ
    Arab J Gastroenterol; 2018 Mar; 19(1):26-32. PubMed ID: 29506913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
    Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study.
    Feng X; Xu R; Du X; Dou K; Qin X; Xu J; Jia W; Wang Z; Zhao H; Yang S; Guo C; Liu T; Ma K
    Am J Gastroenterol; 2014 Dec; 109(12):1891-9. PubMed ID: 25403366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
    Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
    J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medium or Large Hepatocellular Carcinoma: Sorafenib Combined with Transarterial Chemoembolization and Radiofrequency Ablation.
    Zhu K; Huang J; Lai L; Huang W; Cai M; Zhou J; Guo Y; Chen J
    Radiology; 2018 Jul; 288(1):300-307. PubMed ID: 29688153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Fibrosis but Late Tumor Stage and Worse Outcomes in Hepatocellular Carcinoma Patients Without Hepatitis B or Hepatitis C.
    Hsu PY; Hsu CT; Yeh ML; Huang CF; Huang CI; Liang PC; Lin YH; Hsieh MY; Wei YJ; Hsieh MH; Dai CY; Lin ZY; Chen SC; Huang JF; Yu ML; Chuang WL
    Dig Dis Sci; 2020 Jul; 65(7):2120-2129. PubMed ID: 31722058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of TACE and Sorafenib Improves Outcomes in BCLC Stages B/C of Hepatocellular Carcinoma: A Single Centre Experience.
    Varghese J; Kedarisetty C; Venkataraman J; Srinivasan V; Deepashree T; Uthappa M; Ilankumaran K; Govil S; Reddy M; Rela M
    Ann Hepatol; 2017; 16(2):247-254. PubMed ID: 28233748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.
    Chao Y; Chung YH; Han G; Yoon JH; Yang J; Wang J; Shao GL; Kim BI; Lee TY
    Int J Cancer; 2015 Mar; 136(6):1458-67. PubMed ID: 25099027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
    Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
    BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.
    Han K; Kim JH
    World J Gastroenterol; 2015 Sep; 21(36):10327-35. PubMed ID: 26420959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Li L; Zhao W; Wang M; Hu J; Wang E; Zhao Y; Liu L
    BMC Gastroenterol; 2018 Sep; 18(1):138. PubMed ID: 30180810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma.
    Pecorelli A; Lenzi B; Gramenzi A; Garuti F; Farinati F; Giannini EG; Ciccarese F; Piscaglia F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Sacco R; Cabibbo G; Felder M; Morisco F; Gasbarrini A; Baroni GS; Foschi FG; Biasini E; Masotto A; Virdone R; Bernardi M; Trevisani F;
    Liver Int; 2017 Mar; 37(3):423-433. PubMed ID: 27566596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis.
    Piñero F; Marciano S; Fernández N; Silva J; Anders M; Zerega A; Ridruejo E; Romero G; Ameigeiras B; D'Amico C; Gaite L; Bermúdez C; Reggiardo V; Colombato L; Gadano A; Silva M
    World J Gastroenterol; 2019 Jul; 25(27):3607-3618. PubMed ID: 31367160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcatheter Arterial Chemoembolization With or Without Radiofrequency Ablation: Outcomes in Patients With Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma.
    Hirooka M; Hiraoka A; Ochi H; Kisaka Y; Joko K; Michitaka K; Hiasa Y
    AJR Am J Roentgenol; 2018 Apr; 210(4):891-898. PubMed ID: 29412017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Chen L; Su H; Shao H; Xu K; Liang S; Liu J
    Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
    Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
    J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results.
    Cosgrove DP; Reyes DK; Pawlik TM; Feng AL; Kamel IR; Geschwind JF
    Radiology; 2015 Nov; 277(2):594-603. PubMed ID: 26069923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group.
    Farinati F; Vanin V; Giacomin A; Pozzan C; Cillo U; Vitale A; Di Nolfo AM; Del Poggio P; Benvegnu' L; Rapaccini G; Zoli M; Borzio F; Giannini EG; Caturelli E; Trevisani F;
    Liver Int; 2015 Jan; 35(1):223-31. PubMed ID: 25074434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.